Fierce JPM Week: Biotech tinkers with mRNA's winning formula
To view this email as a web page, click here

Today's Rundown

Featured Story

Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began

Hal Barron is leaving GlaxoSmithKline. After four years as chief scientific officer, Barron is leaving to take up the CEO post at a deep-pocketed, wildly ambitious biotech startup—leaving Pfizer veteran Tony Wood in charge of the scientific side of the company.

read more

Top Stories

Eisai takes baton from Biogen as next Alzheimer's prospect follows in Aduhelm's footprints

Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better. Luckily, they get a do-over.

read more

Fierce JPM Week: After 'objectively astonishing' progress on mRNA, biotech looks to tinker with winning formula

Messenger RNA, or mRNA, became a household name so quickly thanks to the COVID-19 vaccines by Pfizer-BioNTech and Moderna. Now, biotech is taking a moment to reflect on where the field goes from here. 

read more

Sponsored: Engineering Biology: The Evolution of the Biopharma Industry

Is biopharma ready to reap the rewards and realize the full potential of synthetic/engineering biology? Jennifer Honeycutt talks about how engineering biology with the right partners could provide new pathways to drug discovery and development, portable cell-free solutions for scalable industrial biomanufacturing on demand, and new preclinical testing methods for better science and smarter biopharma.

read more

Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease

Altos Labs just redefined big in biotech. Where to start? The $3 billion in investor support? The C-suite staffed by storied leaders—Barron, Bishop, Klausner—identifiable by one name? Or the wildly ambitious plan to reverse disease for patients of any age? Altos is all that and more.

read more

Bristol Myers, VCs launch new RNA therapeutics biotech Ceptur with $75M to silence pre-mRNA

Messenger RNA soared to the spotlight with the rollout of COVID-19 vaccines last year, and now a new biotech is looking at silencing pre-mRNA to target cancers, central nervous system diseases and other conditions. Bristol Myers Squibb and multiple venture capital shops are betting $75 million on Ceptur Therapeutics' launch.

read more

Fierce JPM Week: Bayer's new R&D chief wants to push past Aspirin legacy with innovation

As head of global R&D for Bayer, Christian Rommel is attempting to chart a reinvention of research and development at the storied Big Pharma. Recent acquisitions, leadership additions and developments in technology will all have to work in his favor to bring Bayer into the next stage.

read more

Sensorion sinks as lead hearing loss program flounders in phase 2 trial, calling future indications into question

Sensorion's sudden hearing loss med failed to beat placebo at improving hearing sensitivity, but the French biotech will stay mum on further development plans until secondary endpoint data is released in mid-March.

read more

As Pfizer's Cibinqo grabs an FDA green light, JAK inhibitors' entry into the eczema market 'has split doctors' opinion: report

Pfizer believes it’s onto a $3 billion winner after the FDA approval of its dermatitis JAK inhibitor Cibinqo in January, but a new report surveying physicians around the world shows prescribing this class of meds may be a tricky sell for reps.

read more

Low-value care most common among systems with fewer primary care physicians, investor ownership

A recent Johns Hopkins analysis of Medicare claims identified health systems delivering the most low- and no-value medical services to seniors.

read more

Smith & Nephew kicks in $135M for 3D-printed, cementless knee implant maker Engage Surgical

No bone cement, no problem. Smith & Nephew will now offer both cemented and cementless partial knee implants, thanks to the recent acquisition of Engage Surgical and its cement-free technology.

read more

Did BMS set up a subsidiary to avoid paying $1.4B in U.S. taxes? The Senate finance chairman is on the case

Tax avoidance allegations have hovered over major players in the pharmaceutical industry for decades. Some of the biggest names in the business have occasionally faced inquiries or have had to pay up to the Internal Revenue Service. Now, Bristol Myers Squibb is at the center of a U.S. Senator's tax probe.

read more

Resources

Whitepaper: Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial

Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference.

Research: How Buffer Prep Services Alleviate Sudden Spikes in Campaign Volume

Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific

Whitepaper: QC for ex vivo manipulated cell lines and tissues

A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events